Text Size

Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00303446
First received: March 15, 2006
Last updated: January 25, 2011
Last verified: January 2011
History of Changes
Results First Received: December 9, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Kennedy's Disease
Spinal and Bulbar Muscular Atrophy
Interventions: Drug: Dutasteride
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
57 subjects were evaluated at the National Institutes of Health (NIH) Clinical Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
7 subjects were excluded on the basis of screening blood test abnormalities. 50 subjects were randomized.

Reporting Groups
  Description
Placebo Matched placebo, one tablet daily
Dutasteride Dutasteride 500 micrograms, one tablet daily.

Participant Flow:   Overall Study
    Placebo     Dutasteride  
STARTED     25     25  
COMPLETED     23     21  
NOT COMPLETED     2     4  
Withdrawal by Subject                 2                 2  
Death                 0                 1  
Physician Decision                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Placebo Matched placebo, one tablet daily
Dutasteride Dutasteride 500 micrograms, one tablet daily.
Total Total of all reporting groups

Baseline Measures
    Placebo     Dutasteride     Total  
Number of Participants  
[units: participants]
 		  25     25     50  
Age  
[units: participants]
 		     
<=18 years     0     0     0  
Between 18 and 65 years     21     21     42  
>=65 years     4     4     8  
Age  
[units: years]
Mean ± Standard Deviation 		  53.5  ± 9.2     51.9  ± 10.5     53.1  ± 9.5  
Gender  
[units: participants]
 		     
Female     0     0     0  
Male     25     25     50  
Region of Enrollment  
[units: participants]
 		     
United States     25     25     50  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Muscle Strength Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 1

2.  Secondary:   Creatine Kinase, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 2

3.  Secondary:   Manual Muscle Testing, Change From Baseline.   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 3

4.  Secondary:   Adult Myopathy Assessment Tool, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 4

5.  Secondary:   Timed 2-minute Walk, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 5

6.  Secondary:   Swallow Score Average, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 6

7.  Secondary:   Bulbar Rating Scale, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 7

8.  Secondary:   Sensory Nerve Action Potential Average, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 8

9.  Secondary:   Median Compound Muscle Action Potential, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 9

10.  Secondary:   Peroneal Compound Muscle Action Potential, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 10

11.  Secondary:   Motor Unit Nerve Estimation, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 11

12.  Secondary:   Activities of Daily Living, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 12

13.  Secondary:   Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 13

14.  Secondary:   Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 14

15.  Secondary:   International Index for Erectile Function (IIEF), Change From Baseline   [ Time Frame: 0, 12, and 24 months ]
  Show Outcome Measure 15


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Kenneth Fischbeck, M.D.
Organization: National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
phone: 301-435-9318
e-mail: kf@ninds.nih.gov


Publications of Results:


Responsible Party: Kenneth H. Fischbeck, M.D./National Institute of Neurological Disorders and Stroke, National Institutes of Health
ClinicalTrials.gov Identifier: NCT00303446     History of Changes
Other Study ID Numbers: 060113, 06-N-0113
Study First Received: March 15, 2006
Results First Received: December 9, 2009
Last Updated: January 25, 2011
Health Authority: United States: Federal Government